The Technical Analyst
Agile Therapeutics Inc [AGRX]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Agile Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.61% $0.370
America/New_York / 18 apr 2024 @ 15:56
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.54 mill |
| EPS: | -6.71 |
| P/E: | -0.0600 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 6.86 mill |
| Avg Daily Volume: | 0.733 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0600 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.259 - 0.481 ( +/- 30.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-03 | Coiante Scott M | Buy | 20 000 | Common Stock |
| 2023-08-16 | Coiante Scott M | Sell | 0 | Common Stock |
| 2023-06-28 | Welsh Amy | Buy | 13 500 | Common Stock |
| 2023-06-28 | Welsh Amy | Buy | 4 500 | Employee Stock Option (Right to Buy) |
| 2023-06-28 | Korner Paul | Buy | 13 500 | Common Stock |
| INSIDER POWER |
|---|
| 99.58 |
| Last 98 transactions |
| Buy: 13 666 273 | Sell: 187 248 |
Forecast:
16:00 - $0.370
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.370
Forecast 2: 16:00 - $0.370
Forecast 3: 16:00 - $0.370
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.370 (0.61% ) |
| Volume | 0.0151 mill |
| Avg. Vol. | 0.733 mill |
| % of Avg. Vol | 2.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AGRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 08:05:00 - Press Release
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results And Provides Corporate Update
Full year 2023 net revenue increased 80% from 2022 while opex decreased 33% twirla demand and factory sales up 121% and 114% respectively in 2023 vs 2022 company completes pay-off of debt facility in first quarter 2024 twirla demand expected to rebound in first quarter 2024 from decreased demand in fourth quarter 2023 management to host conference call today, thursday, march 28, 2024 at 8:30 a.m. et princeton, n.j.
2024-03-25 16:30:00 - Press Release
Agile Therapeutics Announces Delisting From Nasdaq
Princeton, n.j., march 25, 2024 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx) (“agile therapeutics” or the “company”), a women's healthcare company, today announced that the company has received a final delisting notice from nasdaq.
2024-03-21 06:35:00 - Press Release
Correction - Agile Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results And Provide Business Update On Thursday, March 28, 2024
Princeton, n.j., march 21, 2024 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on thursday, march 28, 2024.
2024-03-20 08:15:00 - Press Release
Agile Therapeutics To Report Fourth Quarter And Full Year 2023 Financial Results And Provide Business Update On Friday, March 22, 2024
Princeton, n.j., march 20, 2024 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on friday, march 22, 2024.
2024-03-13 07:31:00 - Press Release
Agile Therapeutics Completes Pay-off Of Debt And Remains Focused On Business Plan Execution
Elimination of remaining debt to perceptive advisors leaves the company's balance sheet debt free elimination of remaining debt to perceptive advisors leaves the company's balance sheet debt free
Latest News
2024-03-21 06:35:00 - GlobeNewsWire
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024.
2024-03-20 08:15:00 - GlobeNewsWire
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024.
2023-10-26 08:05:00 - GlobeNewsWire
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
2023-09-28 16:19:48 - The Motley Fool
Why Shares of Agile Therapeutics Jumped This Week
Agile is seeing strong revenue growth. The company only has one marketed product, a birth control patch.
2023-09-05 08:05:00 - GlobeNewsWire
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY.
2023-07-26 08:30:00 - GlobeNewsWire
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023.
2023-05-12 19:09:10 - Seeking Alpha
Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Call Transcript
Agile Therapeutics, Inc. (NASDAQ:AGRX ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Matt Riley - Head, Investor Relations Al Altomari - Chairman & Chief Executive Officer Conference Call Participants Oren Livnat - H.C. Wainwright Operator Good day, and thank you for standing by.
2023-05-08 08:00:00 - GlobeNewsWire
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023.
2023-03-21 09:05:00 - GlobeNewsWire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Live Conference Call and Webcast at 4:30 p.m. ET Live Conference Call and Webcast at 4:30 p.m. ET
2023-02-09 09:48:38 - Zacks Investment Research
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.